# Autotelic Bio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/autotelic-bio-co

- Industry: Biotechnology
- Headquarters: Cheongju, South Korea
- Website: www.autotelicbio.com
- Total disclosed funding: $19M
- Latest round: Series B (Mar 28, 2022)
- Investors on record: 16

## About

Located in South Korea, Autotelic Bio Co., Ltd. specializes in the development of innovative cancer therapies, including proprietary Anti-Sense Oligonucleotide (ASO) drugs and small molecule compounds aimed at addressing critical health concerns.Autotelic Bio Co., Ltd. focuses on creating advanced cancer treatments and was founded in 2015 in Cheongju, South Korea. The company has successfully raised a total of KRW 15.5 billion through its most recent Series B funding round on March 28, 2022, with contributions from various investors including Colopl Next and DT&Investment. The CEO, Tae Kim, leads the firm, which has participated in 5 funding deals to date.Autotelic Bio Co., Ltd. is dedicated to developing cutting-edge cancer therapies, prominently featuring its proprietary Anti-Sense Oligonucleotide (ASO) drugs and small molecule compounds. These ASO drugs utilize advanced informatics platforms, such as ASODE+ and CATs, to inhibit disease-related proteins. The firm is actively researching three ASO cancer treatments and two small molecule therapies, including ATB-101 for hypertension and diabetes, and ATB-301 targeting TGF-ß2 in cancer. The products aim to meet the significant health challenges in oncology and chronic disease management, primarily serving markets in the United States and Europe.Operating on a business-to-business model, Autotelic Bio Co., Ltd. generates revenue through partnerships with healthcare institutions and pharmaceutical companies. The company sells its ASO and small molecule therapies directly to hospitals and clinics, along with potential licensing agreements with larger firms. Key products like ATB-320 and ATB-350 are essential to the firm's revenue strategy, addressing specific medical needs in oncology and chronic disease management.Autotelic Bio Co., Ltd. plans to utilize the KRW 15.5 billion raised in the Series B funding round to enhance its clinical research and support global commercialization of immuno-targeted anticancer drugs and hybrid new drugs for hypertension and diabetes. The company is focused on launching new products in the coming years and aims to expand its presence in both the U.S. and European markets. With a commitment to advancing its therapeutic offerings, Autotelic Bio seeks to address the evolving demands in the pharmaceutical landscape.

## Funding rounds

- Series B, Mar 28, 2022, $13M — Woori Bank, JB Investment, Solidus Investment, UTC Investment, DT&Investment, Magna Investment, Colopl Next, Sejong Venture Partners, LSK Investment, IBK Capital, Stonebridge Ventures, DreamStone Partners
- Series A, Feb 1, 2020, $1.3M — Stonebridge Ventures
- Series A, Jan 7, 2020, $5.6M — JB Investment, UTC Investment, Korea Credit Guarantee Fund, Aju Pharm Co., Ltd.
- Seed, Jul 1, 2018 — Korea Tech Incubator for Startup, Ulsan Creative Economy Innovation Center

## Investors

- Korea Tech Incubator for Startup — Seed
- Ulsan Creative Economy Innovation Center (https://capitalatlas.ai/funds/ulsan-creative-economy-innovation-center) — Seed
- JB Investment (https://capitalatlas.ai/funds/jb-investment) — Series A, Series B
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series A, Series B
- Korea Credit Guarantee Fund — Series A
- Aju Pharm Co., Ltd. — Series A
- Stonebridge Ventures — Series A, Series B
- Woori Bank — Series B
- Solidus Investment (https://capitalatlas.ai/funds/solidus-investment) — Series B
- DT&Investment (https://capitalatlas.ai/funds/dt-investment) — Series B
- Magna Investment (https://capitalatlas.ai/funds/magna-investment) — Series B
- Colopl Next (https://capitalatlas.ai/funds/colopl-next) — Series B
- Sejong Venture Partners — Series B
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series B
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series B
- DreamStone Partners (https://capitalatlas.ai/funds/dreamstone-partners) — Series B